[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"walking-difficulty\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:walking-difficulty":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,51,84,115,140,163,192,224,279,308,331,356,429],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100640793","physical-activity-level-at-home-in-cmt1a-patients-wearable-sensor-assessment-100640793",false,"NCT07591779","Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment","Study of the Relationship Between Clinical and Functional Characteristics of Patients With CMT1A Disease and Their Level of Physical Activity at Home Measured Using Portable Electronic Sensors","CMT1A-HOME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis)\n3. Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and\u002For having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges\n4. Ability to walk independently (with or without walking aids)\n5. Informed consent obtained\n6. Affiliated to French social security system\n\nExclusion Criteria:\n\n1. Other associated neurological condition that could independently affect walking or motor activity\n2. Inability to wear the sensor device (skin allergy, sensory intolerance)\n3. Inability to comply with study procedures (cognitive impairment, no fixed domicile)\n4. Participation in another interventional study during the same period\n5. Pregnant or breastfeeding women\n6. Patients under legal protection (guardianship or curatorship)","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.\n\nThis research will:\n\nIn the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel \"Nano-Cur\" treatment currently under development.",[25,26,27,28,29],"Charcot-Marie-Tooth Disease, Type IA","Peripheral Neuropathy Hereditary","Motor Activity","Walking, Difficulty","Neuromuscular Diseases",[31,32,33,34,35,36,37],"CMT1A","wearable sensor","actigraphy","physical activity","CMT-FOM","functional assessment","peripheral neuropathy","NOT_YET_RECRUITING","2026-05-20",{"date":41,"type":42},"2026-05-22","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2027-06-30",{"name":48,"class":49},"University Hospital, Limoges","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100634466","impact-of-loss-aversion-messaging-and-anticipated-regret-for-inaction-on-exercise-adherence-in-older-adults-100634466","NCT07540052","Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults","Testing the Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults: A Randomized Pilot Trial","Inclusion Criteria:\n\n* Completed 12 months of FAST intervention\n\nExclusion Criteria:\n\n* No planned surgeries within the upcoming 4 months","65 Years",{"count":60,"type":21},148,"INTERVENTIONAL",[63],"NA","The goal of this clinical trial is to learn if messages focused on not losing the functional benefits of exercise can help older adults with walking difficulty continue to exercise regularly. The main questions it aims to answer are:\n\nDo these messages make people more likely to anticipate regretting it if they do not exercise? Does more anticipated regret make it more likely they will exercise more regularly?\n\nResearchers will compare two versions of messages to see if the content of these one of these message types is more effective than the other.\n\nParticipants will complete a daily 5-minute at home exercise program for 4 months and complete regular online surveys to track their progress and report their feelings regarding regret.",[66,67],"Mobility Disability","Walking Difficulty",[69,70,71,72,73,74],"exercise adherence","older adults","mobility disability","walking difficulty","pilot study","randomized controlled trial","2026-04-16",{"date":77,"type":42},"2026-04-20",{"date":79,"type":21},"2026-06",{"date":81,"type":21},"2027-07",{"name":83,"class":49},"Milton S. Hershey Medical Center",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":61,"phases":95,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":50},"100546811","phase-2-fisetin-to-reduce-senescence-and-mobility-impairment-in-pad-100546811","NCT06399809","Fisetin to Reduce Senescence and Mobility Impairment in PAD","Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial","FIRST","Inclusion Criteria:\n\nFirst, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:\n\n1. An ankle brachial index (ABI) less than or equal to 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of greater than 0.90 and less than or equal to 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Critical limb ischemia defined as an ABI less than 0.40 with signs or symptoms of critical limb ischemia\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a symptom other than PAD\n5. Current foot ulcer on bottom of foot\n6. Failure to successfully complete the study run-in\n7. Planned major surgery, coronary or leg revascularization during the next five months\n8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.\\]\n10. Mini-Mental Status Examination (MMSE) score less than 23\n11. Allergy to fisetin\n12. Currently taking fisetin or has taken fisetin in previous three months\n13. Non-English speaking\n14. Current participation in or completion of a clinical trial intervention in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a clinical trial (other than stem cell or gene therapy), participants will be eligible after the final study intervention as long as at least three months have passed since the final intervention of the trial.\\]\n15. Visual impairment that limits walking ability.\n16. Six-minute walk distance of less than 500 feet or greater than1600 feet.\n17. Participation in a supervised treadmill exercise program in previous three months.\n18. Participants may be excluded if they are unwilling to undergo a fat biopsy. However, if investigators find recruitment significantly slows due to this exclusion, participants may still be able to participate in the trial if they refuse the fat biopsy.\n19. Women who are not menopausal will be excluded. Menopause is defined as absence of a menstrual period in the past 12 months.\n20. People with a bilirubin above 2.2 mg\u002Fdl, with serum aspartate transaminase (AST) or alanine aminotransferase (ALT) more than four times the upper limit of normal.\n21. Hemoglobin less than 7.0 g\u002Fdl, white blood count less than 2,000\u002Fmm3, white blood count greater than 20,000\u002Fmm3, platelet count less than 40,000\u002FuL.\n22. Estimated glomerular filtration rate (eGFR) less than 25 ml\u002Fmin\u002F1.73 m2\n23. HemoglobinA1C great than 10 as a marker of poor diabetes control.\n24. People who are Human Immunodeficiency Virus positive (HIV+) and people with active hepatitis B or active hepatitis C infections who do not have a low viral load.\n25. People taking warfarin and other sensitive substrates of CYP2C9, CYP2C19, or CYP1A2 that have a narrow therapeutic window will be excluded, unless the drug can be held for at least two days prior to the first day of each study drug administration and can continue to be held for ten hours after the second dose of study drug administration for each of the two days of study drug dosing.\n26. Body mass index (BMI) great than 43.\n27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant. In some instances, patients whose medications or laboratory data meet exclusion criteria may participate at the Principal Investigator's discretion.","50 Years",{"count":94,"type":21},34,[96],"PHASE2","The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and\u002For blood.",[99,100,101,28,102],"Peripheral Arterial Disease","Aging","Peripheral Vascular Diseases","Claudication",[104],"Fisetin","RECRUITING","2026-04-11",{"date":108,"type":42},"2026-04-15",{"date":110,"type":42},"2024-09-30",{"date":112,"type":21},"2027-06",{"name":114,"class":49},"Northwestern University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":61,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":50},"100546818","enhancing-exercise-with-light-to-improve-functioning-in-pad-100546818","NCT06399900","ENhancing Exercise With LIGHT to Improve Functioning in PAD","ENhancing Exercise With LIGHT to Improve Functioning in PAD: the ENLIGHTEN PAD Trial","ENLIGHTEN PAD","Inclusion Criteria:\n\nFirst, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:\n\n1. An ABI \\\u003C= 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure \\\u003C= 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of \\>0.90 and \\\u003C= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Critical limb ischemia defined as an ABI \\\u003C0.40 with symptoms of rest pain\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a symptom other than PAD\n5. Current foot ulcer on bottom of foot\n6. Failure to successfully complete the study run-in\n7. Planned major surgery, coronary or leg revascularization during the next four months\n8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.\\]\n10. Mini-Mental Status Examination (MMSE) score \\\u003C 23\n11. Non-English speaking\n12. Participation in or completion of a clinical trial in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.\\]\n13. Visual impairment that limits walking ability.\n14. Six-minute walk distance of \\\u003C400 feet or \\>1700 feet.\n15. Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months.\n16. Unwilling to avoid red light therapy outside of study participation.\n17. Baseline blood pressure \\\u003C100\u002F45.\n18. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.",{"count":124,"type":21},32,[63],"The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).",[128,129,100,28],"Peripheral Artery Disease","Peripheral Vascular Disease",[131,132,133],"light therapy","peripheral artery disease","exercise",{"date":108,"type":42},{"date":136,"type":42},"2024-08-12",{"date":138,"type":21},"2027-01-31",{"name":114,"class":49},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":61,"phases":149,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100518555","phase-3-smart-exercise-for-pad-100518555","NCT06032065","SMART Exercise for PAD","Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for Peripheral Artery Disease: The SMART PAD Trial","Inclusion Criteria:\n\nFirst, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as either:\n\n1. An ABI \\\u003C= 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of \\>0.90 and \\\u003C1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Limb-threatening ischemia defined as an ABI \\\u003C0.40 with symptoms of rest pain\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a condition other than PAD\n5. Current foot ulcer on bottom of foot\n6. Unwilling to drink beetroot juice\n7. Unwilling to accept randomization into either group (home based exercise or supervised exercise)\n8. Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial.\n9. Already exercising at a level consistent with exercise intervention.\n10. End-stage kidney disease (ESKD) associated with the need for dialysis.\n11. Planned major surgery, coronary or leg revascularization during the next six months\n12. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n13. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.\\]\n14. Mini-Mental Status Examination (MMSE) score \\\u003C 23 or dementia. However, if the MMSE is \\\u003C 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE \\\u003C 23 to participate, as appropriate.\n15. Allergy to beetroot juice\n16. Currently consuming beetroot juice or oral nitrate or nitrite, or a beetroot supplement, and\u002For unwilling to avoid these during study participation. Participants currently consuming one cup of beets daily will be asked to discontinue beet ingestion for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more, they will not be eligible for the clinical trial.\n17. Unstable angina\n18. Abnormal baseline stress test without subsequent clearance for exercise by physician\n19. Non-English speaking. The SMART PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages, nor does it have the ability to translate all study materials into other languages.\n20. Participation in or completion of a clinical trial in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.\\] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice.\n21. Visual impairment that limits walking ability.\n22. Baseline blood pressure \\\u003C100\u002F45.\n23. Participation in a supervised treadmill exercise program or cardiac rehabilitation program in previous three months.\n24. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.\n25. An eGFR value \\\u003C30 or potassium \\>5.0.\n26. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.\n27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.",{"count":148,"type":21},210,[150],"PHASE3","Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times\u002Fweek to a center for SET is burdensome. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. Walking exercise is first line therapy to improve walking distance for PAD, but it does not eliminate ischemic leg symptoms in most people with PAD. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. Participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.",[99,100,101,28],[154,155],"behavior change","patient reported outcome measure",{"date":108,"type":42},{"date":158,"type":42},"2023-09-08",{"date":160,"type":21},"2029-03-31",{"name":114,"class":49},3,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":61,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":190,"locationsCount":50},"100551020","a-motor-learning-intervention-to-target-walking-performance-in-ambulant-children-with-cerebral-palsy-100551020","NCT06454656","A Motor Learning Intervention to Target Walking Performance in Ambulant Children With Cerebral Palsy","A \"MOtor Learning Based Intervention for Lower Extremities (MOBILE)\" to Target Walking Performance in Ambulant Children With Cerebral Palsy: A Feasibility Study","MOBILE","Inclusion Criteria:\n\n* Primary diagnosis of Cerebral Palsy (GMFCS Levels I-III)\n* Has a specific walking related goal\n* Has capacity to follow instruction\n* Has a primary caregiver who can support a home program\n\nExclusion Criteria:\n\n* Has had surgery within 6 months of intervention start date\n* Has had botox\u002F baclofen within 3 months of intervention start date\n* Has a dual diagnosis that impacts ability to follow instruction\n* Has a significant cognitive impairment","6 Years","17 Years",{"count":174,"type":21},14,[63],"The goal of this clinical trial is to learn if a new therapy approach to improve walking ability in children with Cerebral Palsy is acceptable to the children and the families in a community setting.\n\nThe main questions we look to answer are:\n\n1. Do the children\u002Fteens tolerate the therapy and feel that it is helpful?\n2. Do the parents\u002F families feel the therapy helps and is easy to commit to?\n3. Do the children\u002Fteens complete all their therapy sessions and assessments as planned?\n\nThe participants will trial the therapy for 30 hours over 6 weeks and will perform assessments before and after to see if they meet their goals. They will also be interviewed to see how they felt about the therapy when they finish.",[178,28,179,180],"Cerebral Palsy","Spastic Diplegia","Hemiplegic Cerebral Palsy",[182,183,184],"Motor Learning Theory","Neuroplasticity","Neurological Rehabilitation","2026-04-09",{"date":187,"type":42},"2026-04-14",{"date":136,"type":42},{"date":112,"type":21},{"name":191,"class":49},"Royal College of Surgeons, Ireland",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":61,"phases":203,"briefSummary":204,"conditions":205,"keywords":209,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":50},"100520692","biomarkers-of-reaction-to-hiit-exercise-100520692","NCT06059872","Biomarkers of Reaction To HIIT Exercise","What Makes a Responder, a Responder? Biomarkers to Help Identify Responders and Resistors to High-intensity Interval Training for Lower Extremity Chronic Stroke","BReaTHE","Inclusion Criteria:\n\n* chronic left or right subcortical stroke as defined by 6 months or more after a cardiovascular accident\n* lower extremity motor impairment due to stroke that causes a walking speed of less than 0.6 m\u002Fs during a 10m walk\n* Veteran status\n\nExclusion Criteria:\n\n* MRI contraindications, including implanted cardiac pacemakers and severe claustrophobia\n* any neurodegenerative condition other than stroke that may lead to lower extremity impairment\n* a visual or auditory impairment that may hinder study procedures\n* any medical condition that would preclude participation in a physical exercise intervention program","89 Years",{"count":202,"type":21},55,[63],"Stroke survivors with lower limb disability can improve their walking speed with high-intensity interval training (HIIT) rehabilitation therapy. However, some individuals may not respond to HIIT even when fully adherent to the program. To address this, the investigators propose to build a predictive model that identifies if a Veteran with chronic subcortical stroke will improve their walking speed with HIIT by incorporating blood lactate as an early predictor of exercise response, and inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and regional cerebral blood flow (CBF) as predictors of the brain's potential to respond, while also taking into consideration other factors such as comorbidities, demographics, and fitness levels.",[206,207,208,28],"Stroke","Stroke Rehabilitation","Lower Extremity Weakness, Spastic",[210,211,212,213],"Predictors of Stroke Rehabilitation","Biomarkers of Stroke Rehabilitation","Exercise Intervention","Neuroimaging","2026-03-23",{"date":216,"type":42},"2026-03-27",{"date":218,"type":42},"2024-01-01",{"date":220,"type":21},"2027-12-01",{"name":222,"class":223},"VA Office of Research and Development","FED",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":61,"phases":234,"briefSummary":235,"conditions":236,"keywords":246,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":50},"100612195","development-and-efficacy-of-a-novel-cost-effective-gait-training-device-utilized-at-home-for-stroke-survivors-100612195","NCT07250425","Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors","Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* First-ever ischemic or hemorrhagic stroke confirmed by medical record.\n* 3 months to 5 years post-stroke at time of enrollment.\n* Presence of lower-extremity motor impairment limiting walking function.\n* Able to stand for at least 30 minutes with no more than minimal assistance (with or without a device).\n* Medically stable and cleared by a physician to participate in moderate-intensity ambulation exercise.\n* Living in a home environment that can safely accommodate device installation (e.g., adequate space, appropriate flooring, and power access) as determined by the study team.\n* Able to understand study procedures and provide informed consent (or have a legally authorized representative), with sufficient cognitive and communication skills to follow simple instructions.\n* If assistance is required for transfers or device set-up, availability of a caregiver or assistant willing to participate in training and device use.\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).\n* Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).\n* Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.\n* Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.\n* Progressive neurological conditions (e.g., progressive neurodegenerative disease) expected to significantly worsen over the 12-week study period.\n* Current participation in another interventional trial targeting gait or lower-extremity function.\n* Any other condition that, in the opinion of the investigators, would make participation unsafe or interfere with study adherence or outcome interpretation.","75 Years",{"count":233,"type":21},20,[63],"This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.",[206,237,238,239,240,241,67,242,243,244,245],"Neurological Diseases or Conditions","Hemiparesis;Poststroke\u002FCVA","Gait Disorders, Neurologic","Post Stroke Fatigue","Motor Recovery","Balance Impairment","Falls Prevention","Hemiparesis","Mobility Limitation",[247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270],"in-home rehabilitation","Robotic-Assisted Gait Training","gait training device","stroke recovery","functional mobility","rehabilitation technology","remote monitoring","rehabilitation robotics","Fitbit Step Tracking","Self-Directed Gait Training","high-intensity gait training","Neurorehabilitation Research","Lower Limb Rehabilitation","Motor Function Recovery","Physical Therapy","Walking Endurance","task specific walking practice","neurological recovery","stroke rehabilitation","home exercise program","Rise&Walk InHome","daily step count","6-minute walk test","10-meter walk test","2026-03-06",{"date":273,"type":42},"2026-03-09",{"date":275,"type":21},"2026-08",{"date":275,"type":21},{"name":278,"class":49},"Healing Innovations",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":286,"sex":17,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":61,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":50},"100618362","chronic-wounds-and-blood-circulation-detection-100618362","NCT07330635","Chronic Wounds and Blood Circulation Detection","Constructing a Holistic Care New Model for Chronic Wounds and Blood Circulation Detection to Enhance Home Care Quality","Inclusion Criteria:\n\nGeneral criteria (applied to all participants):\n\nWillingness to participate in this study and comply with all study procedures. Able to perform basic physical activity and complete lower limb circulatory and functional assessments.\n\nNormal cognitive function sufficient to understand instructions and provide informed consent.\n\nGroup-specific criteria:\n\nYoung Adults (Control Group):Aged 20-40 years.No known chronic diseases or peripheral circulatory disorders.Considered healthy volunteers.\n\nOlder Adults (Healthy Elderly Group):Aged 65-95 years.No major chronic diseases affecting lower limb circulation.\n\nOlder Adults with Chronic Disease (Impaired Circulation Group):Aged 65-95 years.Diagnosed with one or more conditions known to impair peripheral circulation, including but not limited to peripheral arterial disease (e.g., atherosclerosis, thromboangiitis obliterans), chronic venous insufficiency (e.g., varicose veins), diabetes mellitus, hypertension, or hyperlipidemia.\n\nExclusion Criteria:\n\nRecent acute lower limb injury resulting in tissue exudation, swelling, or other conditions that prevent safe participation in the assessment or intervention procedures.",true,"20 Years","95 Years",{"count":290,"type":21},425,[63],"Lower limb circulatory insufficiency and the associated chronic wounds are common health problems among the elderly. These issues not only affect the individual's mobility and quality of life but also potentially increase medical costs and caregiving expenses. Traditional treatment methods often employ medications to enhance blood circulation, but these clinical approaches have limited effectiveness and induce the risk of side effects. Utilizing exercise as an intervention strategy can help improve lower limb blood circulation in the elderly while reducing the side effects associated with medications. However, due to physical frailty, elderly individuals often cannot participate in high-intensity exercises to improve their circulatory performance.\n\nTherefore, this study will develop a lower limb circulation enhancement exercise system to improve the circulatory performance in individuals with poor lower limb circulation. It will compare the effects of lower limb circulation enhancement exercise, vibration exercise, and mixed exercise on improving blood circulation and functional performance in the elderly or individuals with poor lower limb circulation.\n\nParticipants will be randomly assigned into three groups: the lower limb circulation enhancement exercise group, the vibration exercise group, and the mixed exercise group. In addition, a separate group of young adults (control group) will serve as a reference for baseline comparisons. Initially, all participants will undergo a one-time exercise test, followed by a 12-week intervention. The lower limb circulation enhancement exercise group will perform a 30-minute leg press rowing exercise three times a week, while the vibration exercise group will engage in vibration exercise at the same frequency, and the mixed exercise group will perform group-based mixed exercise training at the same frequency. The young adult control group will not receive any intervention but will undergo the same assessments.\n\nOutcome evaluations before and after the intervention include lower limb blood perfusion monitoring, pain scales, and functional performance assessments.",[100,28,294,295],"Chronic Limb-Threatening Ischemia","Chronic Disease",[297,298,295],"Poor Lower Limb Circulation","Older Adults","2025-12-29",{"date":301,"type":42},"2026-01-09",{"date":303,"type":42},"2024-09-04",{"date":305,"type":21},"2027-12-31",{"name":307,"class":49},"National Health Research Institutes, Taiwan",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":286,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":315,"targetDuration":4,"studyType":61,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100549336","neurophysiological-effects-of-transcutaneous-electrical-nerve-stimulation-in-persons-with-ms-100549336","NCT06432686","Neurophysiological Effects of Transcutaneous Electrical Nerve Stimulation in Persons With MS","Neurophysiological Effects of Transcutaneous Electrical Nerve Stimulation in Persons With MS - a Pilot Study","Inclusion Criteria:\n\n* age: 18-65 years\n* EDSS score \\\u003C 7\n\nExclusion Criteria:\n\n* metal or electrical implants\n* BMI \\> 40\n* claustrophobia\n* being pregnant\n* having a psychiatric disorder\n* having cognitive or communication problems which reduces the capacity to understand instructions\n* having a neurological disorder other than MS\n* having cardiac arrhythmia",{"count":316,"type":21},30,[63],"Transcutaneous Electrical Nerve Stimulation (TENS) is a treatment that could potentially reduce walking problems and fatigue in persons with Multiple Sclerosis. However, extensive use of TENS in a clinical setting is hindered by a lack of neurophysiological understanding of the effects of TENS. The primary objective of this pilot study is therefore to investigate the effects of TENS on brain activity in pwMS measured with fMRI.",[320,28,321],"Fatigue","Multiple Sclerosis","2025-09-03",{"date":324,"type":42},"2025-09-10",{"date":326,"type":21},"2025-10-01",{"date":328,"type":21},"2025-12-31",{"name":330,"class":49},"University Medical Center Groningen",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":61,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":50},"100535109","to-develop-a-walking-exercise-program-for-non-ambulatory-stroke-survivors-100535109","NCT06247553","To Develop a Walking Exercise Program for Non-ambulatory Stroke Survivors","Inclusion Criteria:\n\n* must be 18 to 80 years old\n* male or female\n* independent ambulation before stroke\n* able to understand and follow verbal commands in English\n* have physicians' approval for exercise\n* be in a stable medical condition\n* must be after the first stroke\n* unable to walk independently\n* in the chronic stage (at least 6 months after stroke onset)\n\nExclusion Criteria:\n\n* musculoskeletal or other disorders that prevent the participant from participating in the exercise\n* blood pressure higher than 200\u002F110 mm Hg\n* diagnosis of severe depression\n* functionally restricted passive movement in the major joints of lower limbs\n* unable to speak or understand English\n* unable to travel to the Research Laboratory\n* currently participate in other walking training using treadmill with or without a body-weight support system\n* body weight greater than 400 lbs","80 Years",{"count":339,"type":21},72,[63],"The goal of this clinical trial is to test a gait (walking) training program in non-ambulatory (unable to walk) chronic stroke survivors. The main question it aims to answer is:\n\n• Will gait training improve the cardiovascular system in non-ambulatory chronic stroke survivors better than a sitting leg cycling exercise?\n\nParticipants will walk on a treadmill with a partial body-weight support system and the gait training device. Researchers will compare with a leg-cycling exercise to see if there are significant differences in resting heart rate, systolic blood pressure (SBP), and A1c levels in the blood.",[206,28,343],"Cardiovascular Injury",[345,346],"stroke","unable to walk","2025-07-30",{"date":349,"type":42},"2025-08-01",{"date":351,"type":42},"2024-02-02",{"date":353,"type":21},"2027-09-01",{"name":355,"class":49},"University of Kansas Medical Center",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":363,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":61,"phases":366,"briefSummary":367,"conditions":368,"keywords":387,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":428},"100397880","phase-2-locomotor-training-with-testosterone-to-promote-bone-and-muscle-health-after-spinal-cord-injury-100397880","NCT04460872","Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Locomotor Training With Testosterone to Promote Bone and Muscle Health","Inclusion Criteria:\n\n* Men \\>18 years of age\n* Diagnosis of an incomplete SCI involving spinal segments L1 or above or a clinically complete SCI involving spinal segments T2-L1, with upper motor neuron injury signs (i.e., spasticity, hypertonicity) for \\>60-days\n* Low serum total testosterone (\\\u003C300 ng\u002FdL), bioavailable testosterone (\\\u003C110 ng\u002FdL), or free testosterone (\\\u003C46 pg\u002FmL or \\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign or symptom that may be related to low testosterone, including: loss of body hair or reduced shaving, very small testes (\\\u003C6 mL), reduced sexual desire (libido) and activity, decreased spontaneous erections (e.g., morning erections) or erectile dysfunction, breast discomfort or gynecomastia, height loss, low-trauma fracture, or low BMD, hot flushes or sweats, decreased energy, motivation, initiative, or self-confidence, fatigue or irritability, feeling sad or blue, having a depressed mood, or having a persistent low-grade depressive disorder, poor concentration or memory, sleep disturbances or increased sleepiness, mild unexplained anemia (normochromic or normocytic), reduced muscle bulk, strength, or physical performance, Increased body fat or body mass index, any other sign or symptom commonly associated with low testosterone\n* Locomotor dysfunction, definted as self-selected walking pace ≤1.0 m\u002Fs on a 10mWT, either with or without gait devices or braces and with or without assistance, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairments, as identified by a trained observer.\n* Diagnosis of first time SCI including etiology from trauma, vascular, or orthopedic pathology\n* Medically-stable condition that is asymptomatic for conditions that will interfere with the study participation\n* Willingness to administer TRT as instructed by the study staff and to abide by study protocol\n* Documented approval from the study physician verifying medical status\n\nExclusion Criteria:\n\n* Currently participating in another research protocol that may influence study outcomes.\n* Mental state that precludes understanding the study protocol.\n* Life expectancy \\\u003C12-months.\n* History of or current congenital SCI (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Frederich's ataxis) or other degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate study procedures\n* Multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment or injury\n* Current prostate, breast, or other organ cancer or a history of prostate or breast cancer\n* Any other diagnosed or treated cancer within the past 24-months, with the exceptions of basal or squamous cell carcinoma of the skin that has been successfully treated\n* Serum prostate-specific antigen (PSA) \\>3.0 ng\u002FmL \\[men treated with 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are eligible to participate if PSA values are ≤1.5 ng\u002FmL\\]\n* Prostate nodule or induration noted on digital rectal exam (DRE) during screening that tests positive for prostate cancer\n* Currently seeking fertility or expected during the duration of the study\n* Gynecomastia\n* Hematocrit (HCT) \\>49%\n* Any major cardiovascular (CV) event within the last 12-months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, revascularization of the carotid or middle cerebral artery or procedures to treat critical limb ischemia, or hospitalization due to unstable angina, transient ischemic attack, stroke, or peripheral vascular disease)\n* Angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (NYHA class III or IV)\n* Poorly controlled hypertension (consistently measured systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg), while on medications\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram (ECG) findings such as left bundle branch block or marked ECG abnormalities that would preclude serial screening evaluations for occult ischemic events\n* History of unprovoked deep venous thrombosis (DVT), unprovoked pulmonary embolism, history of recurrent DVT or known thrombophilia\n* LDL cholesterol \\>160 mg\u002FdL with history of any major CV event, defined above, within the last 12-months\n* Major non-CV surgery (e.g., major abdominal or thoracic procedure) within 90-days prior to screening and\u002For a major surgery scheduled at the time of screening\n* Liver enzymes (AST or ALT) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease documented by estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Lower extremity fracture in the last 12-months (exclusion criterion for participation in LT+TRT group only)\n* Femoral neck, total hip, or lumbar spine t-score below -2.5 or distal femur BMD \\\u003C0.70 g\u002Fcm2, assessed via DEXA at screening (exclusion criterion for participation in LT+TRT group only)\n* Current anticoagulant therapy (contraindication for i.m. injections)\n* Use of any of the following pharmacologic agents in the previous 90-days: any TRT formulation, any compounded or over-the-counter androgenic hormones or androgen precursors, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or growth hormone\n* Use of anti-resorptive or bone anabolic drug therapy in the previous 180-days\n* Acute use (\\>5-days) of any opioids (e.g., oxycodone, hydrocodone, etc) or systemic glucocorticoids \\>7.5 mg\u002Fd prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) within 1-week before screening visit, except men who are taking these medications for a chronic condition and are anticipated to continue treatment for the study duration\n* Known allergy to any component of the TRT formulation (e.g., sesame oil or cottonseed oil)\n* Any other condition, therapy, lab abnormality, medical or psychiatric conditions, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive study intervention, or interfere with the person's ability to participate for the entire study duration","MALE",{"count":365,"type":21},21,[96],"This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.",[369,370,371,372,373,374,375,376,377,378,379,380,28,239,381,382,383,384,385,386],"Spinal Cord Injury","Spinal Cord Injuries","Trauma, Nervous System","Wounds and Injury","Central Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male","Spinal Cord Trauma","Injuries, Spinal Cord","Locomotion Disorder, Neurologic","Wounds and Injuries","Nervous System Diseases","Testosterone Deficiency","Androgen Deficiency","Hormone Deficiency",[388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,369],"Testosterone","Testosterone enanthate","Testosterone undecanoate","Testosterone 17 beta-cypionate","Methyltestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Muscle Strength","Muscle Mass","Bone Mineral Density","Adipose Tissue","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Magnetic Resonance Imaging","Walking","Ambulation","Locomotor","Locomotion","Treadmill","2025-05-01",{"date":421,"type":42},"2025-05-06",{"date":423,"type":42},"2021-01-31",{"date":425,"type":21},"2026-06-30",{"name":427,"class":49},"North Florida Foundation for Research and Education",2,{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":17,"minAge":436,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":61,"phases":440,"briefSummary":441,"conditions":442,"keywords":444,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":50},"100548419","phase-2-passive-stretching-in-peripheral-arterial-disease-patients-100548419","NCT06420752","Passive Stretching in Peripheral Arterial Disease Patients","Passive Stretching and Dietary Nitrate Rescue Functional Capacity in Peripheral Arterial Disease","Inclusion Criteria:\n\nAnkle-brachial index of 0.90 or less Stable condition for at least 3 months\n\nExclusion Criteria:\n\nHabitual exercise or cardiovascular rehabilitation program during the past 3 months Critical limb ischemia, amputation, or leg pain at rest Major surgery or lower extremity revascularization in the last 3 months Heart Failure Kidney disease Beet allergy Crohn's Current smoker","40 Years","90 Years",{"count":439,"type":21},64,[96],"Peripheral artery disease (PAD) leads to higher mortality rates and strains healthcare systems due to increased costs. It causes leg pain during walking due to reduced blood flow. Nitric oxide (NO) deficiency contributes to vascular issues in PAD, with few effective treatments available. Passive calf muscle stretching boosts NO levels, vascular health, and walking ability in PAD patients. However, the inflammatory processes underlying these improvements are unclear. This study aims to track inflammatory markers and cardiovascular changes during 12 weeks of passive stretching. Additionally, combining stretching with dietary nitrate could further enhance walking capacity by reducing reactive oxygen species. The study will monitor inflammation, vascular function, and oxidative capacity to understand the effects on functional ability in PAD patients. This research is crucial for improving physical function and addressing exercise intolerance in PAD.",[99,28,443],"Inflammation",[445],"Cardiovascular","2025-03-27",{"date":448,"type":42},"2025-04-02",{"date":450,"type":42},"2024-05-20",{"date":452,"type":21},"2029-12-31",{"name":454,"class":49},"University of Wisconsin, La Crosse"]